id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-1136-0075,FDA,FDA-2020-D-1136,"Guidance Documents Related to
Coronavirus Disease 2019; Availability",Notice,Notice of Availability,2021-10-06T04:00:00Z,2021,10,2021-10-06T04:00:00Z,,2023-05-12T20:07:03Z,2021-21798,0,0,0900006484dbc502
FDA-2020-D-1136-0074,FDA,FDA-2020-D-1136,Development of Abbreviated New Drug Applications During the COVID-19 Pandemic – Questions and Answers; Guidance for Industry,Other,Guidance,2021-09-08T04:00:00Z,2021,9,2021-09-08T04:00:00Z,2023-05-12T03:59:59Z,2023-05-08T18:53:09Z,,0,0,0900006484d5f1ce
FDA-2020-D-1136-0073,FDA,FDA-2020-D-1136,Guidance Documents Related to Coronavirus Disease 2019; Availability,Notice,Notice of Availability,2021-07-23T04:00:00Z,2021,7,2021-07-23T04:00:00Z,,2023-05-12T20:06:35Z,2021-15649,0,0,0900006484c097c2
FDA-2020-D-1136-0066,FDA,FDA-2020-D-1136,Guidance: Documents Related to Coronavirus Disease 2019; Availability,Notice,Notice of Availability,2021-05-27T04:00:00Z,2021,5,2021-05-27T04:00:00Z,,2023-05-12T20:06:17Z,2021-11217,0,0,0900006484b3ca2f
FDA-2020-D-1136-0062,FDA,FDA-2020-D-1136,Guidance Documents Related to  Coronavirus Disease 2019; Availability,Notice,Notice of Availability,2021-04-26T04:00:00Z,2021,4,2021-04-26T04:00:00Z,,2024-11-06T23:46:13Z,2021-08474,1,0,0900006484ab6bbf
FDA-2020-D-1136-0057,FDA,FDA-2020-D-1136,"Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the 
COVID-19 Public Health Emergency; Guidance for Industry",Other,Guidance,2021-04-14T04:00:00Z,2021,4,2021-04-14T04:00:00Z,,2024-11-06T23:47:11Z,,1,0,0900006484aa70cf
FDA-2020-D-1136-0056,FDA,FDA-2020-D-1136,"Development of Abbreviated New Drug Applications During the COVID-19 Pandemic – Questions and Answers - Guidance for Industry - April 2021
U.S. Department of Health and Human Services
Food and Drug Administration
Center for",Other,Guidance,2021-04-07T04:00:00Z,2021,4,2021-04-07T04:00:00Z,2023-05-12T03:59:59Z,2023-05-08T18:53:55Z,,0,0,0900006484a9f1b6
FDA-2020-D-1136-0051,FDA,FDA-2020-D-1136,COVID-19 Container Closure System and Component Changes: Glass Vials and Stoppers Guidance for Industry March 2021,Other,Guidance,2021-03-05T05:00:00Z,2021,3,2021-03-05T05:00:00Z,2021-03-05T04:59:59Z,2024-11-12T23:30:07Z,,1,0,0900006484a60779
FDA-2020-D-1136-0050,FDA,FDA-2020-D-1136,"Development of Monoclonal Antibody Products Targeting SARS-CoV-2, Including Addressing the Impact of Emerging Variants, During the COVID-19 Public Health Emergency - Guidance for Industry - February 2021",Other,Guidance,2021-02-22T05:00:00Z,2021,2,2021-02-22T05:00:00Z,,2024-11-12T23:30:16Z,,1,0,0900006484a459a4
FDA-2020-D-1136-0049,FDA,FDA-2020-D-1136,Guidance Documents Related to Coronavirus Disease 2019; Availability,Notice,Notice of Availability,2021-02-19T05:00:00Z,2021,2,2021-02-19T05:00:00Z,,2024-11-12T23:27:55Z,2021-03421,1,0,0900006484a42ed9
FDA-2020-D-1136-0047,FDA,FDA-2020-D-1136,COVID-19: Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins  Targeting SARS-CoV-2 Infectivity; Guidance for Industry,Other,Guidance,2021-01-22T05:00:00Z,2021,1,2021-01-22T05:00:00Z,,2024-11-06T23:44:17Z,,1,0,09000064849fccda
FDA-2020-D-1136-0046,FDA,FDA-2020-D-1136,Protecting Participants in Bioequivalence Studies for Abbreviated New Drug Applications During the COVID-19 Public Health Emergency Guidance for Industry,Other,Guidance,2021-01-19T05:00:00Z,2021,1,2021-01-19T05:00:00Z,2023-05-12T03:59:59Z,2023-05-08T18:56:13Z,,0,0,09000064849f89c5